Loading clinical trials...

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -

NCT02191930•University of Cologne

View on ClinicalTrials.gov

Summary

The purpose of this trial is to determine 1. Objective response rate (ORR), defined as the proportion of patients having CR, CRr or PR in the centrally reviewed restaging after six cycles of chemotherapy 2. Progression-free survival (PFS) 3 years after registration

Eligibility

Age

60 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•classical Hodgkin Lymphoma
•Age 60 years or older
•ECOG performance status ≤ 2 or ≤ 3 if due to HL
•CIRS-G score of ≤ 6 and ≤ 3 per organ system (except score 4 for eye, ear, nose and throat)
•Advanced stages: Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease
•written informed consent
•classical Hodgkin Lymphoma
•Age 60 years or older
•stage IA to IVB
•CIRS-G score of ≥ 7 or 4 in one organ system (except score 4 for eye, ear, nose and throat)

Exclusion Criteria

•Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)
•Prior chemotherapy or radiation for HL except prephase
•Peripheral neuropathy greater than CTC Grade 1
•written informed consent
•Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL)
•Prior chemotherapy or radiation for HL except prephase as outlined in the protocol
•Peripheral neuropathy greater than CTC Grade 1

Locations (1)

1st Dept. of Medicine, Cologne University Hospital

Cologne, Germany

Key Dates

Start Date

September 1, 2015

Primary Completion Date

March 16, 2022

Completion Date

March 16, 2022

Last Updated

August 23, 2024

Enrollment

ACTUAL participants

Conditions

Hodgkin Lymphoma

Interventions

B-CAP

DRUG

Brentuximab Vedotin

DRUG

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

NCT05529069

Mantle Cell LymphomaNon Hodgkin Lymphoma+1 more

View study

RECRUITINGPHASE1

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

NCT06189391

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 23, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Inclusion Criteria

Exclusion Criteria

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma